Current Report Filing (8-k)
February 21 2023 - 01:59PM
Edgar (US Regulatory)
0001419051 false 0001419051 2023-02-21
2023-02-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported):
February 21, 2023
|
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. |
|
(Exact
Name of Registrant as Specified in its Charter) |
|
Nevada |
|
000-54554 |
|
45-1226465 |
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
|
701 Wild Rose Lane |
|
Elk City,
Idaho
83525 |
|
(Address
of Principal Executive Offices and Zip Code) |
|
|
|
(760)
295-7208 |
|
(Issuer’s
telephone number) |
|
|
|
|
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Item
1.01 Entry into a Material Definitive Agreement
On
February 17, 2023, Therapeutic Solutions International, Inc. and
Veltmeyer Institute for Advanced Biologics, LLC, entered into an
exclusive patent license agreement for Right to Try, emergency
Investigational New Drug (“IND”), and/or Expanded Access use within
the field of brain and lung for those conditions that are
applicable included here in exhibit 10.1. In exchange TSOI has
received 30% of Veltmeyer Institute Management Company,
LLC.
Item
8.01 Other Events.
The information set forth in Item 1.01 of this Current Report on
Form 8-K is incorporated herein by reference including reference to
exhibits.
Item
9.01 Financial Statements and Exhibits.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
February 21, 2023 |
|
|
|
|
|
|
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
|
| |
|
|
| By: |
/s/
Timothy Dixon |
|
| |
Timothy
Dixon |
|
| |
Chief
Executive Officer |
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From May 2023 to Jun 2023
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jun 2022 to Jun 2023
